{
  "schemaVersion": 1,
  "organisationId": "O-db95cd816a4e41a395ab3aa8c6d7c4de",
  "slug": "beam-therapeutics-inc",
  "name": "Beam Therapeutics Inc.",
  "updatedAt": "2026-10-02T12:12:57.824776Z",
  "sections": [
    {
      "type": "OVERVIEW",
      "text": "Beam Therapeutics Inc. is a clinical-stage biotechnology company developing precision genetic medicines using a proprietary base-editing platform, designed to make targeted single-letter DNA changes without double-strand breaks. Its development work includes genetic diseases such as sickle cell disease, beta-thalassemia, alpha-1 antitrypsin deficiency and glycogen storage disease type 1a. The company’s stated vision is to provide lifelong cures for people with serious diseases. [P145836616][P145836619][P145836333][https://beamtx.com/about-us/]\n\nBeam is based in Cambridge, Massachusetts, and also has a manufacturing facility in Durham, North Carolina. For FY2025, it reported $139.743 million in license and collaboration revenue; it reported no product-sales revenue to date in its Q2 2026 filing. Revenue for the six months ended June 30, 2026 was $32.228 million. A third-party source estimates 511 employees at year-end 2025. [T12184205][P145836693][T16688336][https://beamtx.com/locations/cambridge/][https://beamtx.com/locations/research-triangle-park/][https://stockanalysis.com/stocks/beam/employees/]\n[P145836616][P145836619][P145836333][T12184205][P145836693][T16688336][https://beamtx.com/about-us/][https://beamtx.com/locations/cambridge/][https://beamtx.com/locations/research-triangle-park/][https://stockanalysis.com/stocks/beam/employees/]",
      "updatedAt": "2026-10-02T12:12:57.824776Z"
    },
    {
      "type": "PRODUCTS",
      "text": "Beam Therapeutics’ investigational products include **risto-cel (ristoglogene autogetemcel; formerly BEAM-101)**, an autologous hematopoietic stem-cell therapy for sickle cell disease. Its base edits are designed to mimic naturally occurring variants associated with hereditary persistence of fetal hemoglobin. The Phase 1/2 BEACON trial completed dosing of adult and adolescent patients; the company said a biologics license application could be submitted as early as year-end 2026. [P145836621][P145836623][P145836634]\n\n**BEAM-302** is a liver-targeted lipid nanoparticle (LNP) base-editing candidate intended to correct the SERPINA1 E342K/PiZ mutation that causes alpha-1 antitrypsin deficiency. Its Phase 1/2 study was ongoing, and a global pivotal cohort began dosing in July 2026. **BEAM-301** uses liver-targeted LNP delivery to correct the G6PC R83C mutation associated with glycogen storage disease Ia; its Phase 1/2 trial was dosing patients in cohort two. **BEAM-304** is a liver-targeted candidate designed to correct disease-causing PAH mutations in phenylketonuria; after FDA clearance of its investigational new drug application in June 2026, the company began start-up for a Phase 1/2 trial initially focused on the R408W mutation. [P145836641][P145836149][P145836151][P145836669][P145836670][P145836665][P145836667]\n\n**BEAM-103** is an anti-CD117 monoclonal antibody being studied as a non-genotoxic conditioning agent to support potential ex vivo and in vivo sickle cell disease therapies; it is an enabling candidate rather than a gene-editing treatment. Beam’s base-editing platform uses CRISPR-guided editing designed to modify individual DNA bases without making double-stranded DNA breaks. Its LNP platform delivers base-editor mRNA and guide RNA for in vivo editing. The company reported no product-sales revenue to date, and its disclosures did not identify a separate productized service offering. [P145836174][P145836616][P145836639][P145836693]\n[P145836621][P145836623][P145836634][P145836641][P145836149][P145836151][P145836669][P145836670][P145836665][P145836667][P145836174][P145836616][P145836639][P145836693]",
      "updatedAt": "2026-10-02T12:12:57.824776Z"
    },
    {
      "type": "GEOGRAPHY",
      "text": "Beam Therapeutics’ disclosed operating footprint is in the United States. Its principal executive office is in Cambridge, Massachusetts; the 2025 Form 10-K reports about 130,258 square feet of office and laboratory space there. The company also has a 100,000-square-foot manufacturing facility in Research Triangle Park, North Carolina, for manufacturing capabilities supporting its programs. [P145836317][P85517912][P15517205] Beam identifies Cambridge as its biotech hub and Research Triangle Park as its manufacturing-facility location. [https://beamtx.com/locations/cambridge/][https://beamtx.com/locations/research-triangle-park/]\n\nBeam reports one operating segment and describes its operations as exclusively in the United States; the cited disclosures do not provide revenue by country or region. [P24878888][P32440740] The 2025 Form 10-K reports 511 full-time team members, with counts by job function, but does not give employee numbers by location or geography. [P27024050]\n[P145836317][P85517912][P15517205][https://beamtx.com/locations/cambridge/][https://beamtx.com/locations/research-triangle-park/][P24878888][P32440740][P27024050][https://beamtx.com/locations/cambridge/][https://beamtx.com/locations/research-triangle-park/]",
      "updatedAt": "2026-10-02T12:12:57.824776Z"
    },
    {
      "type": "SEGMENTS",
      "text": "Beam Therapeutics reports a single operating and reportable segment: its consolidated business. It does not report separate segments for individual programs, therapeutic areas, or delivery approaches. The sole segment therefore represents 100% of reported operations, but the company does not disclose revenue percentages by program or other business category. [P16613045][P24878888]\n\nThe company’s segment activities encompass development of precision genetic medicines using its base-editing platform, including ex vivo and in vivo approaches. These are descriptions of its platform and activities, not separately reported segments. [P101320203]\n[P16613045][P24878888][P101320203]",
      "updatedAt": "2026-10-02T12:12:57.824776Z"
    },
    {
      "type": "HISTORY",
      "text": "Beam Therapeutics was incorporated and began operations in January 2017. Its public launch followed in May 2018, when co-founders David R. Liu, Feng Zhang, and J. Keith Joung announced the company’s focus on base-editing technology. [https://www.sec.gov/Archives/edgar/data/1745999/000119312520031290/d842502dex31.htm] [https://www.businesswire.com/news/home/20180514005400/en/Beam-Therapeutics-Founded-Gene-Editing-Pioneers-Create]\n\nBeam went public on Nasdaq in February 2020. In 2021, it acquired Guide Therapeutics to add delivery technology and a lipid library. In 2022, it entered a multi-target in-vivo base-editing research collaboration with Pfizer and helped launch Orbital Therapeutics to develop RNA medicines. [https://www.sec.gov/Archives/edgar/data/1745999/000119312520026941/d221975d424b4.htm] [https://www.nasdaq.com/press-release/beam-therapeutics-announces-acquisition-of-guide-therapeutics-2021-02-23] [https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-beam-enter-exclusive-multi-target-research] [P5243303]\n\nThe company moved base-editing programs into clinical testing in 2023: it reported first-patient dosing in the BEAM-201 trial that September and in the BEAM-101 sickle-cell trial in the fourth quarter. In 2024, it reported first-patient dosing in the BEAM-302 trial for alpha-1 antitrypsin deficiency. [https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-announces-first-patient-dosed-phase-12-trial] [https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-highlights-progress-across-base-editing/] [https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-announces-first-patient-dosed-phase-12-study/]\n[https://www.sec.gov/Archives/edgar/data/1745999/000119312520031290/d842502dex31.htm][https://www.businesswire.com/news/home/20180514005400/en/Beam-Therapeutics-Founded-Gene-Editing-Pioneers-Create][https://www.sec.gov/Archives/edgar/data/1745999/000119312520026941/d221975d424b4.htm][https://www.nasdaq.com/press-release/beam-therapeutics-announces-acquisition-of-guide-therapeutics-2021-02-23][https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-beam-enter-exclusive-multi-target-research][P5243303][https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-announces-first-patient-dosed-phase-12-trial][https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-highlights-progress-across-base-editing/][https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-announces-first-patient-dosed-phase-12-study/][https://www.sec.gov/Archives/edgar/data/1745999/000119312520031290/d842502dex31.htm][https://www.businesswire.com/news/home/20180514005400/en/Beam-Therapeutics-Founded-Gene-Editing-Pioneers-Create][https://www.sec.gov/Archives/edgar/data/1745999/000119312520026941/d221975d424b4.htm][https://www.nasdaq.com/press-release/beam-therapeutics-announces-acquisition-of-guide-therapeutics-2021-02-23][https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-beam-enter-exclusive-multi-target-research][https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-announces-first-patient-dosed-phase-12-trial][https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-highlights-progress-across-base-editing/][https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-announces-first-patient-dosed-phase-12-study/]",
      "updatedAt": "2026-10-02T12:12:57.824776Z"
    }
  ],
  "sources": [
    {
      "id": "P145836616",
      "href": "https://app.finbar.com/go?id=P145836616",
      "label": "Beam Therapeutics Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-c51e35ee5a5347b189b9c5986faa24ad"
    },
    {
      "id": "P145836619",
      "href": "https://app.finbar.com/go?id=P145836619",
      "label": "Beam Therapeutics Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-c51e35ee5a5347b189b9c5986faa24ad"
    },
    {
      "id": "P145836333",
      "href": "https://app.finbar.com/go?id=P145836333",
      "label": "Beam Therapeutics Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-c51e35ee5a5347b189b9c5986faa24ad"
    },
    {
      "id": "https://beamtx.com/about-us/",
      "href": "https://beamtx.com/about-us/",
      "label": "beamtx.com"
    },
    {
      "id": "T12184205",
      "href": "https://app.finbar.com/go?id=T12184205",
      "label": "Beam Therapeutics Inc. — Full financial report (2025 Y)",
      "documentId": "D-b3d7cdddc6884cef97fec60d0af640bb"
    },
    {
      "id": "P145836693",
      "href": "https://app.finbar.com/go?id=P145836693",
      "label": "Beam Therapeutics Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-c51e35ee5a5347b189b9c5986faa24ad"
    },
    {
      "id": "T16688336",
      "href": "https://app.finbar.com/go?id=T16688336",
      "label": "Beam Therapeutics Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-c51e35ee5a5347b189b9c5986faa24ad"
    },
    {
      "id": "https://beamtx.com/locations/cambridge/",
      "href": "https://beamtx.com/locations/cambridge/",
      "label": "beamtx.com"
    },
    {
      "id": "https://beamtx.com/locations/research-triangle-park/",
      "href": "https://beamtx.com/locations/research-triangle-park/",
      "label": "beamtx.com"
    },
    {
      "id": "https://stockanalysis.com/stocks/beam/employees/",
      "href": "https://stockanalysis.com/stocks/beam/employees/",
      "label": "stockanalysis.com"
    },
    {
      "id": "P145836621",
      "href": "https://app.finbar.com/go?id=P145836621",
      "label": "Beam Therapeutics Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-c51e35ee5a5347b189b9c5986faa24ad"
    },
    {
      "id": "P145836623",
      "href": "https://app.finbar.com/go?id=P145836623",
      "label": "Beam Therapeutics Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-c51e35ee5a5347b189b9c5986faa24ad"
    },
    {
      "id": "P145836634",
      "href": "https://app.finbar.com/go?id=P145836634",
      "label": "Beam Therapeutics Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-c51e35ee5a5347b189b9c5986faa24ad"
    },
    {
      "id": "P145836641",
      "href": "https://app.finbar.com/go?id=P145836641",
      "label": "Beam Therapeutics Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-c51e35ee5a5347b189b9c5986faa24ad"
    },
    {
      "id": "P145836149",
      "href": "https://app.finbar.com/go?id=P145836149",
      "label": "Beam Therapeutics Inc. — Press release (2026 Q 2)",
      "documentId": "D-054ea1ac92a746d2a5767b0ddb7a3041"
    },
    {
      "id": "P145836151",
      "href": "https://app.finbar.com/go?id=P145836151",
      "label": "Beam Therapeutics Inc. — Press release (2026 Q 2)",
      "documentId": "D-054ea1ac92a746d2a5767b0ddb7a3041"
    },
    {
      "id": "P145836669",
      "href": "https://app.finbar.com/go?id=P145836669",
      "label": "Beam Therapeutics Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-c51e35ee5a5347b189b9c5986faa24ad"
    },
    {
      "id": "P145836670",
      "href": "https://app.finbar.com/go?id=P145836670",
      "label": "Beam Therapeutics Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-c51e35ee5a5347b189b9c5986faa24ad"
    },
    {
      "id": "P145836665",
      "href": "https://app.finbar.com/go?id=P145836665",
      "label": "Beam Therapeutics Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-c51e35ee5a5347b189b9c5986faa24ad"
    },
    {
      "id": "P145836667",
      "href": "https://app.finbar.com/go?id=P145836667",
      "label": "Beam Therapeutics Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-c51e35ee5a5347b189b9c5986faa24ad"
    },
    {
      "id": "P145836174",
      "href": "https://app.finbar.com/go?id=P145836174",
      "label": "Beam Therapeutics Inc. — Press release (2026 Q 2)",
      "documentId": "D-054ea1ac92a746d2a5767b0ddb7a3041"
    },
    {
      "id": "P145836639",
      "href": "https://app.finbar.com/go?id=P145836639",
      "label": "Beam Therapeutics Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-c51e35ee5a5347b189b9c5986faa24ad"
    },
    {
      "id": "P145836317",
      "href": "https://app.finbar.com/go?id=P145836317",
      "label": "Beam Therapeutics Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-c51e35ee5a5347b189b9c5986faa24ad"
    },
    {
      "id": "P85517912",
      "href": "https://app.finbar.com/go?id=P85517912",
      "label": "Beam Therapeutics Inc. — Full financial report (2025 Y)",
      "documentId": "D-b3d7cdddc6884cef97fec60d0af640bb"
    },
    {
      "id": "P15517205",
      "href": "https://app.finbar.com/go?id=P15517205",
      "label": "Beam Therapeutics Inc. — Full financial report (2025 Y)",
      "documentId": "D-b3d7cdddc6884cef97fec60d0af640bb"
    },
    {
      "id": "P24878888",
      "href": "https://app.finbar.com/go?id=P24878888",
      "label": "Beam Therapeutics Inc. — Full financial report (2025 Y)",
      "documentId": "D-b3d7cdddc6884cef97fec60d0af640bb"
    },
    {
      "id": "P32440740",
      "href": "https://app.finbar.com/go?id=P32440740",
      "label": "Beam Therapeutics Inc. — Full financial report (2025 Y)",
      "documentId": "D-b3d7cdddc6884cef97fec60d0af640bb"
    },
    {
      "id": "P27024050",
      "href": "https://app.finbar.com/go?id=P27024050",
      "label": "Beam Therapeutics Inc. — Full financial report (2025 Y)",
      "documentId": "D-b3d7cdddc6884cef97fec60d0af640bb"
    },
    {
      "id": "P16613045",
      "href": "https://app.finbar.com/go?id=P16613045",
      "label": "Beam Therapeutics Inc. — Full financial report (2026 Q 1)",
      "documentId": "D-cfd209d14d5b43ffba6ebf5c3aef2d1d"
    },
    {
      "id": "P101320203",
      "href": "https://app.finbar.com/go?id=P101320203",
      "label": "Beam Therapeutics Inc. — Full financial report (2025 Y)",
      "documentId": "D-b3d7cdddc6884cef97fec60d0af640bb"
    },
    {
      "id": "https://www.sec.gov/Archives/edgar/data/1745999/000119312520031290/d842502dex31.htm",
      "href": "https://www.sec.gov/Archives/edgar/data/1745999/000119312520031290/d842502dex31.htm",
      "label": "www.sec.gov"
    },
    {
      "id": "https://www.businesswire.com/news/home/20180514005400/en/Beam-Therapeutics-Founded-Gene-Editing-Pioneers-Create",
      "href": "https://www.businesswire.com/news/home/20180514005400/en/Beam-Therapeutics-Founded-Gene-Editing-Pioneers-Create",
      "label": "www.businesswire.com"
    },
    {
      "id": "https://www.sec.gov/Archives/edgar/data/1745999/000119312520026941/d221975d424b4.htm",
      "href": "https://www.sec.gov/Archives/edgar/data/1745999/000119312520026941/d221975d424b4.htm",
      "label": "www.sec.gov"
    },
    {
      "id": "https://www.nasdaq.com/press-release/beam-therapeutics-announces-acquisition-of-guide-therapeutics-2021-02-23",
      "href": "https://www.nasdaq.com/press-release/beam-therapeutics-announces-acquisition-of-guide-therapeutics-2021-02-23",
      "label": "www.nasdaq.com"
    },
    {
      "id": "https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-beam-enter-exclusive-multi-target-research",
      "href": "https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-beam-enter-exclusive-multi-target-research",
      "label": "www.pfizer.com"
    },
    {
      "id": "P5243303",
      "href": "https://app.finbar.com/go?id=P5243303",
      "label": "Beam Therapeutics Inc. — Full financial report (2022 Y)",
      "documentId": "D-27781693cf46419594232faabfbaee22"
    },
    {
      "id": "https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-announces-first-patient-dosed-phase-12-trial",
      "href": "https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-announces-first-patient-dosed-phase-12-trial",
      "label": "investors.beamtx.com"
    },
    {
      "id": "https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-highlights-progress-across-base-editing/",
      "href": "https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-highlights-progress-across-base-editing/",
      "label": "investors.beamtx.com"
    },
    {
      "id": "https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-announces-first-patient-dosed-phase-12-study/",
      "href": "https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-announces-first-patient-dosed-phase-12-study/",
      "label": "investors.beamtx.com"
    }
  ]
}